STO Fellows’ Forum (STOFF)

Due to the COVID-19 pandemic, the 2021 Fellows’ Forum has been postponed until the 4th quarter of 2021. More details about the Forum and application deadlines will be made available by Spring 2021.

 

Society for Translational Oncology Fellows' Forum (STOFF) is an intensive 3-day workshop that brings together fellows and junior faculty within 5 years of training completion from the leading medical, surgical, radiation, and pediatric oncology groups and subspecialty fellowships to educate these rising stars on issues around and barriers to successful translational cancer research. A distinguished faculty of prominent scientists, clinicians, ethicists, industry representatives, and biotech investors serve as mentors.

2020 STOFF Agenda (PDF)

STOFF 2020 Presentations

Cancer Drug Development: Views from Academia
Bernardo H.L. Goulart, MD, MS
University of Washington
Seattle Cancer Care Alliance, Seattle, Washington, USA
 

Cancer Drug Development: Views from Industry
Peter Hammerman, MD
Novartis Institutes for Biomedical Research
Cambridge, Massachusetts, USA
 

The Cost and Value of Cancer Medicine
Thomas Roberts, MD
Farallon Capital Management
San Francisco, California, USA
 

Oncology Drug Development: A Regulatory Perspective
Tatiana Prowell, MD
US Food and Drug Administration,
Silver Spring, Maryland, USA
 

Overcoming Barriers in Career Development and Progression
Ross Levine, MD
Memorial Sloan Kettering Cancer Center,
New York, New York, USA
 

Solving the Achilles Heel of Cancer Immunotherapy
Chloé Villani, PhD
Harvard Medical School, Massachusetts General Hospital
Charlestown, Massachusetts, USA
 

Science at the Interface between the Lab and the Clinic
Ryan Corcoran, MD, PhD
Massachusetts General Hospital Cancer Center,
Boston, Massachusetts, USA
 

CAR T Cells and Toxicities/Efficacy
Bianca Santomasso, MD
Memorial Sloan Kettering Cancer Center
New York, New York, USA
 

Phase I Clinical Trials: Hypothesis Testing
Keith Flaherty, MD
Massachusetts General Hospital Cancer Center,
Boston, Massachusetts, USA
 

Issues in Design of Translational Research Trials
Susan Hilsenbeck, PhD
Baylor College of Medicine,
Houston, Texas, USA
 

IRB Issues and Translational Research PI Responsibilities and Conflict of Interest
Stacey Berg, MD
Texas Children’s Cancer Center, Texas Children’s Hospital,
Baylor College of Medicine, Houston, Texas, USA
 

Quantitative and Systems Pharmacology Approach to Personalizing Therapy
Michael Maitland, MD
Schar Cancer Institute, Inova Health System,
Annandale, Virginia, USA
 

Immune Checkpoint Inhibition in Advanced Cancer
Michael Postow, MD
Memorial Sloan Kettering Cancer Center
New York, New York. USA
 

Therapeutic Resistance Including Serial Biopsy, Rapid Autopsy and Blood-based Biomarkers Platforms
Dejan Juric, MD
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, USA
 

STO gratefully acknowledges educational grant support from: